Premier Alternatives

Profluent

Biotechnology · Emeryville, CA · Founded 2022 · Privately Held (backing)

Developer of artificial intelligence-driven models designed to create and validate novel proteins for biomedicine. Profluent is based in Emeryville, CA and was founded in 2022. It was valued at $525 million at its early-stage round in Nov 2025, the last priced event on record. It has raised $150 million across 2 recorded rounds; the latest was a $106 million Series B in Nov 2025.

PMV mark · valuation
$525.0M
Oct 2026
Priced at
its early-stage round
Nov 2025
Total raised
$150.0M
Last round
Early Stage VC (Series B)
Nov 2025

Profluent key facts

as of Oct 2026
  • Developer of artificial intelligence-driven models designed to create and validate novel proteins for biomedicine.
  • Profluent is valued at approximately $525.0M as of Oct 2026, set at its early-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $150.0M across 2 recorded rounds; the latest was Early Stage VC (Series B) ($106.0M) in Nov 2025.
  • Notable investors include Insight Partners (New York), Spark Capital, Jeff Dean, Altimeter Capital Management, AIX Ventures — 10 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$525.0M

Valued at $525.0M at its early-stage round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Profluent with a free account
  • ·Watch Profluent: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Profluent funding rounds

2 rounds
Nov 2025Early Stage VC (Series B)$106.0M▮
Mar 2024Early Stage VC$35.0M▮
Full funding history →

Profluent valuation

Profluent was valued at $525 million at its early-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Profluent raised?

Profluent has raised $150 million across 2 recorded rounds since 2024. The largest was a $35 million early-stage round in Mar 2024; the most recent was a $106 million Series B in Nov 2025.

Profluent investors

10 investors are on record for Profluent, including Insight Partners (New York), Spark Capital, Jeff Dean and Altimeter Capital Management. By type, the record holds 4 venture capital firms, 1 family office and 1 private equity firm. The Series B in Nov 2025 drew 4 investors.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: DNA Script ($660 million), Odyssey Therapeutics ($638 million) and bit.bio ($546 million).

About Profluent

Developer of artificial intelligence-driven models designed to create and validate novel proteins for biomedicine. The company's platform leverages deep generative models trained on billions of biological sequences, enabling the healthcare industry to optimize across diverse functional attributes in enzymes, antibodies, gene editors, and peptides.

Industry
Biotechnology
Sector
Healthcare
HQ
Emeryville, CA, United States
Founded
2022
Employees
50
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.